EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引：2

作者：

Mease, P. J. ^{[1
,2
]}

Deodhar, A. ^{[3
]}

Van der Heijde, D. ^{[4
]}

Behrens, F. ^{[5
]}

Kivitz, A. ^{[6
]}

Lehman, T. ^{[7
]}

Wei, L. ^{[8
]}

Nys, M. ^{[9
]}

Banerjee, S. ^{[10
]}

Nowak, M. ^{[11
]}

机构：

[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[3] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA

[4] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands

[5] Goethe Univ, Translat Med & Pharmacol ITMP, CIRI Rheumatol & Fraunhofer Inst, Frankfurt, Germany

[6] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[7] Bristol Myers Squibb, Rheumatol, Princeton, NJ USA

[8] Bristol Myers Squibb, Med Immunol, Princeton, NJ USA

[9] Bristol Myers Squibb, GBS Biostat, Braine Lalleud, Belgium

[10] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA

[11] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2021-eular.2653

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0227

引用

页码：137 / 138

页数：2